The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

published in the September 2024 issue of Oncology by O’Brien et al. Resistance to neoadjuvant chemoradiation therapy (neo-CRT) presents a substantial clinical challenge in the management of locally ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Despite improvement in pathologic complete response with preoperative chemoradiation, the benefit did not extend to overall ...

Locally advanced cervical cancer accounts for around 40% of all cervical cancers.1 Cisplatin-based chemoradiotherapy followed ...

However, "the addition of preoperative chemoradiation improved pathological outcomes, with a doubling of the pathological complete response rate, and increased tumor downstaging," Leong said. He ...

The following is a summary of “Dose-response relationships between radiation exposure, bone marrow function as measured by ...

BPM31510, combined with Vitamin K and standard chemoradiation, is being tested in a single-arm Phase 2b trial across four U.S. sites, with a total target enrollment of 50 patients.

Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...

Long-term outcomes in the ITT population as well as those receiving long-term exposure to tislelizumab plus chemotherapy as treatment for first line squamous NSCLC in RATIONALE-307 show a continued OS ...